Form 4: Zura Bio Ltd. Executive Kim Davis Reports Stock Option Grant

Kim Davis, Chief Legal Officer of Zura Bio Ltd., reports the acquisition of stock options for 420,000 Class A Ordinary Shares.

Summary

• On June 18, 2024, Kim Davis, the Chief Legal Officer of Zura Bio Ltd., was granted stock options to purchase 420,000 Class A Ordinary Shares.
• The exercise price of these options is $3.38 per share.
• The options vest over time, with one-fourth vesting on June 18, 2025, and the remaining shares vesting in equal quarterly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future, but it's not overwhelmingly positive as it's a routine event.

Positives

• The grant of stock options to a key executive like the Chief Legal Officer can be seen as an incentive to align their interests with the long-term success of the company.

Risks

• The vesting schedule is contingent upon the Reporting Person's continuous service, so there is a risk that the options may not fully vest if the Reporting Person leaves the company before the vesting is complete.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant and the vesting schedule are typical for executive-level positions, aligning with industry norms for incentivizing long-term commitment and performance.
• Comparable companies in the biotech industry, such as BioNTech or Moderna, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the executive to work towards the company's success, which benefits employees and other stakeholders.

Key Dates